Online Program Home
My Program

Abstract Details

Activity Number: 626 - Health Policy and Real World Evidence with Administrative Data and Electronic Health Records
Type: Contributed
Date/Time: Thursday, August 2, 2018 : 8:30 AM to 10:20 AM
Sponsor: Health Policy Statistics Section
Abstract #328782
Title: Real World Data and Evidence in Health Care Decision Making
Author(s): Kun Chen* and Weili He and Hongwei Wang and Yabing Mai and Qiming Liao
Companies: AbbVie Inc and AbbVie and AbbVie Inc and AbbVie, Inc and AbbVie Inc
Keywords: Real-World Data; Real-World Evidence; Transpaarency; Reproducibility ; Healthcare decision-making; Observational Studies

Currently, most regulatory bodies use real-world data and evidence (RWD/RWE) as supportive information to evaluate the treatment safety but not effectiveness. Use of RWD/RWE in health care decision making attracts increasing attention. Retrospective/prospective observational studies leveraging electronic health data in hospital billing and medical records, as well as other clinical and administrative data, provide a broader representation of real clinical practice and patient population than those found in traditional randomized controlled trials (RCTs).The FDA's PDUFA VI has set up the timeline to publish draft guidance on usage of RWD/RWE on the evaluation of safety and the approval of additional indications of an approved product. EMA has published multiple guidance documents on conducting post-authorization safety and effectiveness studies. However, many challenges and barriers exist. Transparency and reproducibility issues of RWD/RWE are the major concerns. In this presentation, we will define RWD/RWE, illustrate the potential benefits, provide the considerations for generating the RWD/RWE with examples, discuss proposals to fit healthcare decision-making purpose.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program